Jubilant Pharmova Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

EBITDA margin expansionRelated-party transactionsResults View source PDF Explain this filing

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.3%Reaction day

₹1180.20

prior close

₹1113.50

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.9%-3.2% vs market

Pharmaceuticals peers, median of 149sector+0.8%-3.1% vs sector

On the reaction day the stock moved 3.2 pts less than Nifty Smallcap 250 and 3.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.3

10m

+3.5

15m

+3.3

30m

+3.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.3+0.9-3.2+0.8-3.1

Next day

+4.5+0.8+3.7+0.9+3.6

+1.2-0.1+1.3-0.1+1.3

-2.5-1.7-0.8-2.1-0.5

-2.8-0.8-2.0-1.4-1.4

-5.1-1.1-4.0-2.0-3.1

-6.6-2.4-4.2-3.3-3.3

15d

-8.2-0.6-7.6-3.1-5.1

-14.0-3.8-10.2-5.2-8.8

-9.7-2.9-6.8-5.7-4.0

-3.5+1.5-5.0-5.2+1.7

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 149Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jubilant Pharmova reported Q1 FY26 consolidated revenue of ₹1,901 crore, up about 9.8% from ₹1,732 crore a year ago. Profit before exceptional items and tax rose nearly 49% to ₹154 crore, reflecting strong margin expansion across segments like Radiopharma (₹869 crore), CDMO Sterile Injectables (₹393 crore) and CRDMO (₹311 crore). However, reported net profit fell sharply to ₹103 crore (EPS ₹6.49) versus ₹482 crore last year, mainly because the prior year quarter included a one-time exceptional gain of about ₹396 crore that did not recur. On a standalone basis, the API business has been classified as discontinued operations ahead of its slump sale to wholly-owned subsidiary Jubilant Biosys Limited, expected to complete by September 1, 2025. Statutory auditor Walker Chandiok & Co LLP issued a clean limited review report with no qualifications on both sets of results.

Likely market impact

The headline PAT drop looks negative on the surface, but the underlying business actually showed healthy revenue growth, stronger margins, and lower finance costs, suggesting core operations are improving. The API divestment simplifies the portfolio into focused, higher-margin businesses like Radiopharma and CDMO, which should be viewed positively by investors.